Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nick Newton"'
Autor:
Richard Laugharne, Indermeet Sawhney, Bhathika Perera, Delia Wainwright, Paul Bassett, Briony Caffrey, Maire O'Dwyer, Kirsten Lamb, Mike Wilcock, Ashok Roy, Katy Oak, Sharon Eustice, Nick Newton, James Sterritt, Ruth Bishop, Rohit Shankar
Publikováno v:
BJPsych Open, Vol 10 (2024)
Background One-third to half of people with intellectual disabilities suffer from chronic constipation (defined as two or fewer bowel movements weekly or taking regular laxatives three or more times weekly), a cause of significant morbidity and prema
Externí odkaz:
https://doaj.org/article/521eeaec5a8c41e58333019dc03d77a6
Autor:
Wei Yang, Mari Christensen, Jennifer K. Chan, Julie Tsai, Nancy Patten, Ha B. Tran, Grant R. Hillman, Yu Chuan Tai, Patrick Bogard, Claudia M. Litterst, Victoria H. Brophy, Nick Newton, Christopher D. Nelson, Wouter J. Pattje
Publikováno v:
Cancer Research. 82:5156-5156
Non-small cell lung cancer (NSCLC) patients harboring activating mutations in epidermal growth factor receptor (EGFR) are benefited from Tyrosine Kinase Inhibitor (TKI) targeted therapy. However, more than 50% of patients receiving the first or secon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1df76bd403e928248f8c31dde0f7c5a
https://doi.org/10.1158/1538-7445.am2022-5156
https://doi.org/10.1158/1538-7445.am2022-5156
Publikováno v:
The American Journal of Medicine. 124:e13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03f598c3524ecdc0cfb132c7e7ff084d
https://doi.org/10.1016/j.amjmed.2011.03.004
https://doi.org/10.1016/j.amjmed.2011.03.004
Publikováno v:
The American Journal of Medicine. 123:638-645.e4
Background Atrial fibrillation is associated with substantial mortality and morbidity from stroke and thromboembolism. Despite an efficacious oral anticoagulation therapy (warfarin), atrial fibrillation patients at high risk for stroke are often unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8592e15d4be4a851001bc3e4c32cef5
https://doi.org/10.1016/j.amjmed.2009.11.025
https://doi.org/10.1016/j.amjmed.2009.11.025
Publikováno v:
Blood. 112:4659-4659
Background: Acute lymphoblastic leukemia is a hematological malignancy, characterized by overproduction of immature white blood cells in the bone marrow. Highrisk forms of ALL are typically characterized by poor treatment response, short remission du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d823238916f735c1eee9546d6ffc9e73
https://doi.org/10.1182/blood.v112.11.4659.4659
https://doi.org/10.1182/blood.v112.11.4659.4659
Publikováno v:
Blood. 110:5178-5178
Background: Imatinib (Gleevec) is recommended first-line therapy for treatment of chronic myeloid leukemia (CML). A relatively small group of patients treated with imatinib develop resistance or are intolerant to the treatment. Dose escalation of ima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec622eef6a3c1a8cdab8a27e218bb24c
https://doi.org/10.1182/blood.v110.11.5178.5178
https://doi.org/10.1182/blood.v110.11.5178.5178